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A B S T R A C T
Background
Febrile neutropenia (FN) and other infectious complications are some of the most serious treatment-related toxicities of chemotherapy
for cancer, with a mortality rate of 2% to 21%. The two main types of prophylactic regimens are granulocyte (macrophage) colony-
stimulating factors (G(M)-CSF) and antibiotics, frequently quinolones or cotrimoxazole. Current guidelines recommend the use of
colony-stimulating factors when the risk of febrile neutropenia is above 20%, but they do not mention the use of antibiotics. However,
both regimens have been shown to reduce the incidence of infections. Since no systematic review has compared the two regimens, a
systematic review was undertaken.
Objectives
To compare the efficacy and safety of G(M)-CSF compared to antibiotics in cancer patients receiving myelotoxic chemotherapy.
Search methods
We searched The Cochrane Library, MEDLINE, EMBASE, databases of ongoing trials, and conference proceedings of the American
Society of Clinical Oncology and the American Society of Hematology (1980 to December 2015). We planned to include both full-
text and abstract publications. Two review authors independently screened search results.
Selection criteria
We included randomised controlled trials (RCTs) comparing prophylaxis with G(M)-CSF versus antibiotics for the prevention of
infection in cancer patients of all ages receiving chemotherapy. All study arms had to receive identical chemotherapy regimes and other
supportive care. We included full-text, abstracts, and unpublished data if sufficient information on study design, participant charac-
teristics, interventions and outcomes was available. We excluded cross-over trials, quasi-randomised trials and post-hoc retrospective
trials.
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Data collection and analysis
Two review authors independently screened the results of the search strategies, extracted data, assessed risk of bias, and analysed data
according to standard Cochrane methods. We did final interpretation together with an experienced clinician.
Main results
In this updated review, we included no new randomised controlled trials. We included two trials in the review, one with 40 breast cancer
patients receiving high-dose chemotherapy and G-CSF compared to antibiotics, a second one evaluating 155 patients with small-cell
lung cancer receiving GM-CSF or antibiotics.
We judge the overall risk of bias as high in the G-CSF trial, as neither patients nor physicians were blinded and not all included patients
were analysed as randomised (7 out of 40 patients). We considered the overall risk of bias in the GM-CSF to be moderate, because of
the risk of performance bias (neither patients nor personnel were blinded), but low risk of selection and attrition bias.
For the trial comparing G-CSF to antibiotics, all cause mortality was not reported. There was no evidence of a difference for infection-
related mortality, with zero events in each arm. Microbiologically or clinically documented infections, severe infections, quality of life,
and adverse events were not reported. There was no evidence of a difference in frequency of febrile neutropenia (risk ratio (RR) 1.22;
95% confidence interval (CI) 0.53 to 2.84). The quality of the evidence for the two reported outcomes, infection-related mortality
and frequency of febrile neutropenia, was very low, due to the low number of patients evaluated (high imprecision) and the high risk
of bias.
There was no evidence of a difference in terms of median survival time in the trial comparing GM-CSF and antibiotics. Two-year
survival times were 6% (0 to 12%) in both arms (high imprecision, low quality of evidence). There were four toxic deaths in the GM-
CSF arm and three in the antibiotics arm (3.8%), without evidence of a difference (RR 1.32; 95% CI 0.30 to 5.69; P = 0.71; low
quality of evidence). There were 28% grade III or IV infections in the GM-CSF arm and 18% in the antibiotics arm, without any
evidence of a difference (RR 1.55; 95% CI 0.86 to 2.80; P = 0.15, low quality of evidence). There were 5 episodes out of 360 cycles
of grade IV infections in the GM-CSF arm and 3 episodes out of 334 cycles in the cotrimoxazole arm (0.8%), with no evidence of a
difference (RR 1.55; 95% CI 0.37 to 6.42; P = 0.55; low quality of evidence). There was no significant difference between the two arms
for non-haematological toxicities like diarrhoea, stomatitis, infections, neurologic, respiratory, or cardiac adverse events. Grade III and
IV thrombopenia occurred significantly more frequently in the GM-CSF arm (60.8%) compared to the antibiotics arm (28.9%); (RR
2.10; 95% CI 1.41 to 3.12; P = 0.0002; low quality of evidence). Neither infection-related mortality, incidence of febrile neutropenia,
nor quality of life were reported in this trial.
Authors’ conclusions
As we only found two small trials with 195 patients altogether, no conclusion for clinical practice is possible. More trials are necessary to
assess the benefits and harms of G(M)-CSF compared to antibiotics for infection prevention in cancer patients receiving chemotherapy.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic antibiotics or G(M)-CSF for the prevention of infections in cancer patients undergoing chemotherapy
Review question
We reviewed the existing literature examining the efficacy and safety of granulocyte (macrophage) colony-stimulating factors (G(M)-
CSF) compared to antibiotics to prevent infections for cancer patients receiving chemotherapy.
Background
Cancer treatment with chemotherapy (anti-cancer drugs) disrupts the immune system and lowers white blood cell counts. This increases
a person’s risk of infection. Both G(M)-CSF and antibiotics can reduce the risk of infection associated with cancer treatments. The
review compared the efficacy of antibiotics to G(M)-CSFs for the prevention of infection.
Study characteristics
We searched several medical databases and identified two randomised controlled trials (RCT) that met our inclusion criteria; no new
trials were identified for this review update. One trial included 40 breast cancer patients receiving high-dose chemotherapy. Eighteen
patients received G-CSF and 22 got antibiotics (ciprofloxacin and amphotericin) to prevent infection. Another trial evaluated GM-
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CSF versus antibiotics in patients with small-cell lung cancer, with 78 patients in the GM-CSF arm and 77 patients in the antibiotics
arm.
Key results
The study that analysed G-CSF versus antibiotics did not report all cause mortality, microbiologically or clinically documented
infections, severe infections, quality of life, or adverse events. We found no evidence of a difference between the two prophylactic
options for the outcomes of infection-related mortality (no patient died because of infection), or febrile neutropenia.
The trial that assessed GM-CSF versus antibiotics did not found any evidence of a difference in all cause mortality, trial mortality,
infections, or severe infections. The only difference between the two arms was found for the adverse event thrombocytopenia, favouring
patients receiving antibiotics. Quality of life was not reported in this trial.
More research is needed to determine the best prevention against infection in cancer patients.
Quality of the evidence
The quality of the evidence for infection-related mortality and frequency of febrile neutropenia in the G-CSF trial was very low, because
of the small number of patients that were evaluated, and the study design (high risk of bias). The trial that analysed GM-CSF versus
antibiotics reported overall survival, toxic deaths, infections, severe infections, and adverse events. Because of the very small number of
patients included, we judged that the overall quality for all these outcomes was low.
The evidence is current to December 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
G-CSF compared with antibiotics for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
Patient or population: cancer patients receiving myelotoxic chemotherapy
Intervention: G-CSF
Comparison: antibiotics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antibiotics G-CSF
All cause mortality see comment not reported
Infection-related mortality see comment 40
(1 RCT)
⊕©©©1,2
very low
no patient died of infec-
tious causes during the
18-week duration of the
trial
Quality of life see comment not reported
Incidence of febrile neu-
tropenia
318 per 1000 388 per 1000
(169 to 904)
RR 1.22
(0.53 to 2.84)
40
(1 RCT)
⊕©©©1,2
very low
Incidence of severe infec-
tions
see comment not reported
Adverse events see comment not reported
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points)
2 high risk of performance bias (neither patients nor physicians blinded) and detection bias (no intention to treat analysis) (downgraded
by 1 point)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Cancer pa-
tients receiving myelosuppressive therapy or haematopoetic stem
cell transplantation are at increased risk of febrile neutropenia and
infectious complications. The risk of febrile neutropenia and sub-
sequent infection is directly related to the duration and severity of
neutropenia (Bodey 1966; Bodey 1986). Infectious complications
constitute major dose-limiting side effects in patients undergoing
myelosuppressive therapy. Special risk circumstances, such as pa-
tient age greater than 65 years or poor performance status, im-
pact the associated morbidity and mortality (Kuderer 2006; Pizzo
1999). The mortality rate associated with febrile neutropenia in
cancer patients is between 2%and 21% (Smith 2015). In addition,
infectious complications are a common cause of dose reductions
during chemotherapy treatment.
Febrile neutropenia (FN) can be prevented by a prophylactic reg-
imen. Prophylaxis started at the beginning of the first chemother-
apy cycle or in parallel with documented or anticipated neutrope-
nia is called primary prophylaxis, whereas prophylaxis given to
patients who had already experienced episodes of FN in an earlier
chemotherapy cycle, is referred to as secondary prophylaxis. Effec-
tive prophylaxis, using either colony-stimulating factors (CSF) or
antibiotics (or both), would decrease clinically relevant negative
outcomes such as all cause mortality, infection-related mortality,
and infectious complications. Given the high costs of the conse-
quences of FN, and also of the colony-stimulating factors them-
selves, economic arguments are introduced into discussions on the
best prophylactic strategy (Kuderer 2006; Leibovici 2006).
In clinical trials addressing the prevention of FN, granulocyte-
macrophage colony-stimulating factors (GM-CSFs) have been re-
ported to be effective in reducing the duration and severity of che-
motherapy-induced febrile neutropenia (Johnston 2000; Holmes
2002). Prophylaxis, using antibiotics, has also been shown to be
beneficial with reduced fever, incidence of infections and hospi-
talisations (Bucaneve 2005; Cullen 2005).
Description of the intervention
Colony-stimulating factors (CSF)
The current American Society of Clinical Oncology (ASCO)
guidelines justify the administration of CSFs in clinical settings
where the expected risk of suffering FN is approximately 20%
(Smith 2015). In addition to themyelotoxicity of the planned che-
motherapy regimen, patient-specific risk factors should be taken
into account. Secondary prophylaxis with CSFs is recommended
for patients who have developed a neutropenic complication in a
previous chemotherapy cycle, and in whom a reduced dose might
compromise disease-free or overall survival, or treatment out-
come. The guidelines from the Infectious Diseases Working Party
(AGIHO) of the German Society for Haematology and Medical
Oncology (DGHO) give similar recommendations (Vehreschild
2014).
Thus far, randomised controlled trials (Crawford 1991; Trillet-
Lenoir 1993), and subsequent meta-analyses, have shown that
primary prophylaxis with CSFs is effective in reducing FNin pa-
tients with both solid and haematological malignancies (Bohlius
2008; Hackshaw 2004; Lyman 2002; Sung 2004; Sung 2007;
Wittman 2006). Furthermore, GM-CSFs may decrease hospitali-
sation and the use of intravenous therapeutic antibiotics (Crawford
1991; Trillet-Lenoir 1993). In a meta-analysis on the use of G-
CSFs in cancer patients hospitalised with established FN, the au-
thors observed a possible benefit of adding GM-CSFs to antibi-
otic treatment on infection-related mortality and length of hospi-
talisation(Clark 2005). A meta-analysis by Kuderer 2006 showed
that under certain standard dose chemotherapy regimens, early
and infection-related mortality were also reduced with primary G-
CSF prophylaxis. However, none of the meta-analyses with less
restrictive inclusion criteria were able to demonstrate that pro-
phylactic administration of GM-CSFs improved overall survival
when compared to placebo or no treatment. None of these analy-
ses addressed the question of GM-CSFs versus antibiotics, which
is a question closer to clinical reality. One group did a subgroup
analysis of studies in which the published report mandated an-
tibiotic prophylaxis compared to those that did not, and found
no difference between the groups (Sung 2007). This may be due
to the high number of trials where no information about antibi-
otic prophylaxis use is available. In addition, this meta-analysis
included studies that analysed cycles of chemotherapy as opposed
to patients. The distorting effect of such an analysis is difficult to
estimate.
Of the many meta-analyses looking at GM-CSF versus placebo or
no treatment, only one meta-analysis, restricted to patients with
lymphoma,was published inThe Cochrane Library (Bohlius 2008).
This analysis found a reduction in the rate of infections (odds
ratio (OR) 0.74; 95% CI 0.64 to 0.85) but no effect on infection-
related mortality (OR 1.37 favouring control; 95% CI 0.66 to
2.82).
GM-CSF is usually well tolerated, with only a moderate number
of adverse events, mostly bone pain and headaches, however, there
are some hints of increased risk of acute myeloid leukaemia or
myelodysplastic syndromes (Lyman 2010).
Antibiotics
During the last decade, prophylaxis with antibiotics was studied in
a number of randomised clinical trials. The evidence provided was
not considered to be entirely convincing, because none of the stud-
ies were sufficiently large to provide conclusive evidence on the real
efficacy of prophylaxis (Bucaneve 2005; Cullen 2005; Karp 1987;
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Lew 1995). Subsequent meta-analyses suggested that prophylaxis
using antibiotics reduced the incidence of gram-negative bacte-
rial infection, total infection, fever episodes, and hospitalisation
(Cruciani 2003; Engels 1998). Moreover, a meta-analysis of data
on antibiotic prophylaxis (or more specifically, fluoroquinolones)
compared to placebo or no intervention demonstrated that not
only infections were reduced, but all cause mortality, and infec-
tion-related mortality were too (Gafter-Gvili 2005; Gafter-Gvili
2012; Leibovici 2006). One important question which is still
unanswered is whether prophylaxis should be considered for all
patients with cancer and neutropenia. In another meta-analysis
on antibiotic prophylaxis, the majority of patients were suffering
from haematological malignancies and received high-dose chemo-
therapy and bone marrow transplantation, with only a few studies
focusing on solid tumours (Cullen 2005; Gafter-Gvili 2012). An-
other factor possibly compromising the results of the main meta-
analysis was that studies were included that randomised chemo-
therapy cycles and not patients, or reported cycle-based outcomes,
as opposed to a true incidence (where the number of patients and
not cycles are analysed). No information on GM-CSFs compared
to antibiotics was available from these analyses.
How the intervention might work
Colony-stimulating factors
Granulocyte colony-stimulating factors (G-CSF) predominantly
augment the proliferation, maturation, and release of neutrophils,
resulting in a dose-dependent increase in circulating neutrophils
(Bronchud 1988; Morstyn 1988). It is a growth factor for the
myeloid lineage that stimulates the growth of granulocytes and
eosinophil colonies; granulocyte (macrophage) colony-stimulat-
ing factors (GM-CSF) also stimulate the growth of macrophages
(Griffin 1990). Both colony-stimulating factors have shown com-
parable results in decreasing the incidence and duration of neu-
tropenia and fever after chemotherapy. However, there is a lack
of formal comparisons between the two drugs. Probably due to
the macrophage activation caused by GM-CSF, but not G-CSF,
tolerability of GM-CSF has been reported to be inferior. Injection
site reactions in particular, seem more frequent with GM-CSF
(Alvarado 1999; Beveridge 1997; Beveridge 1998; Fischmeister
1999; Hovgaard 1992). Given the undesired additional effects of
GM-CSF and concerns of tumour stimulation by GM-CSF, the
drug has becomemore or less disregarded by recent clinical studies
and guidelines (Smith 2015). Granulocyte (macrophage) colony-
stimulating factors is no longer commercially available in several
European countries for infection prophylaxis. It is licensed formo-
bilisation of stem cells, and after autologous or allogeneic stem cell
transplantation (Smith 2015).
Antibiotics
Antibiotic prophylaxis, most often using flouroquinolones, re-
duces infections by targeting potential pathogens, and in contrast
to G-CSFs it does not provoke the dose-limiting effect of haema-
tological toxicity. A major concern of a routine prophylactic use
of antibiotics in patients with cancer and neutropenia is that it in-
creases bacterial resistance to these agents. This, in turn, may com-
promise the treatment success of both current and future serious
infections by expanding (multi)resistance. In addition, hypersen-
sitivity reactions, gastrointestinal toxicities, and the promotion of
fungal overgrowth after antibiotics put the patient at risk of poten-
tially serious adverse events. These factors may limit their efficacy
in reducing infection-related morbidity or mortality (Carratala
1995; Gafter-Gvili 2007; Somolinos 1992).
Why it is important to do this review
The best prophylactic treatment of febrile neutropenia and infec-
tions in cancer patients receiving antineoplastic therapy remains
controversial, and in general, international guidelines concentrate
on either antibiotics or G-CSFs. The evidence outlined above sug-
gests that prophylaxis with an antibiotic might be as effective as
with G-CSFs for reducing both infections and mortality.
The aim of this systematic review is to provide a comprehensive
overview on the benefits and harms of G-CSF compared to an-
tibiotics for infection prophylaxis in cancer patients. By systemat-
ically identifying all randomised trials conducted to date and by
conducting a critical review of their reliability and validity, we will
mitigate the statistical limitations of individual studies.
O B J E C T I V E S
To compare the efficacy and safety of G-CSF or GM-CSF com-
pared to antibiotics in cancer patients receiving myelotoxic che-
motherapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs). We ex-
cluded cross-over trials and quasi-randomised trials. We included
full-text, abstracts, and unpublished data if sufficient information
on study design, participant characteristics, interventions and out-
comes was available.
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Types of participants
We planned to include paediatric and adult, male and female pa-
tients with a confirmed diagnosis of any type of cancer who were
undergoing myelotoxic chemotherapy. Both solid and haemato-
logical malignancies were eligible.
Types of interventions
We included trials comparing G-CSF or GM-CSF to antibiotics
in the primary prophylaxis of infection-related complications. Tri-
als that examined pegylated G-CSF (pegfilgrastim) were eligible,
provided pegfilgrastim was given once, 24 hours after the comple-
tion of chemotherapy.
Comparison 1
• G-CSF versus antibiotics
Comparison 2
• GM-CSF versus antibiotics
Trials looking at secondary prophylaxis, defined as prophylaxis in a
patientwho suffered fromFN in an earlier course of chemotherapy,
were also eligible, but a subgroup analysis was planned. However,
we did not identify any trial evaluating secondary prophylaxis.
We included studies in which the intended chemotherapy regimen
and supportive care did not differ between study arms. Therefore,
we excluded studies that compared dose-intensified, dose-acceler-
ated, or dose-dense regimens with standard chemotherapy, as this
resulted in different chemotherapy protocols in the arm that re-
ceived antibiotic prophylaxis and the arm that received CSF pro-
phylaxis. Trials with more than two arms were included, provided
at least two arms with the relevant comparison had the same che-
motherapy protocol.
We excluded trials using G-CSF, GM-CSF, or antibiotics to treat
febrile neutropenia, fever, or infections.
Types of outcome measures
Primary outcomes
• Overall survival
• All cause mortality (including infection-related, treatment-
related, or on-trial mortality)
• Infection-related mortality
Studies focusing solely on the efficacy of prophylaxis will most
likely have short-term follow-up only, mainly providing informa-
tion on early mortality. Determining the cause of death in severely
ill patients can be associated with measurement bias. Therefore,
we extracted all cause mortality, comprising infection-related and
treatment-related mortality.
Secondary outcomes
• Microbiologically or clinically documented infections, or
both
◦ We accepted any definition of clinically documented
or microbiologically documented infections given by authors. If
available, we extracted data on all, not only severe, clinically or
microbiologically documented infections. Microbiologically
documented infections were required to have some kind of
cultural confirmation of the infection. Infections reported
without information on microbiological confirmation were
considered to be clinically documented infections.
• Severe infections
• Frequency of febrile neutropenia (FN; any definition of
fever and neutropenia accepted)
• Quality of life (QoL; if measured with a validated QoL
instrument)
• Adverse events
Search methods for identification of studies
For this updated review, we revised the search strategy used for
the first review. We used search strategies based on those described
in Chapter 6 of the Cochrane Handbook for Systematic Reviews
of Interventions (Lefebvre 2011). We did not use any language
constraints.
Electronic searches
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; The Cochrane Library, December 2015; see
Appendix 1)
• MEDLINE (1980 to December 2015; for search strategy
see Appendix 2)
• EMBASE (1980 to January 2008; for search strategy see
Appendix 3)
Since we revised our searches, we re-ran them for CENTRAL and
MEDLINE for the entire period, i.e. 1980 to 2015.
Searching other resources
We searched conference proceedings of the following annualmeet-
ings, which were not included in CENTRAL for abstracts:
• American Society of Hematology (ASH) from 2000 to 2015
• American Society of Clinical Oncology (ASCO) from 2000
to 2015
• European Hematology Association (EHA) from 2000 to
2015
We electronically searched the database of ongoing trials:
• Metaregister of controlled trials
We handsearched the following references:
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• References of all identified trials, relevant review articles and
current treatment guidelines
Data collection and analysis
Selection of studies
Two review authors (NS, OB) independently screened the results
of the search strategies for eligibility by reading the abstracts. In
the case of disagreement, we obtained the full-text publication.
If no consensus could be reached, we consulted a third review
author, in accordance with Chapter 7 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
We documented the study selection process in a flow chart as rec-
ommended in the PRISMA statement (Moher 2009), showing the
total numbers of retrieved references and the numbers of included
and excluded studies.
Data extraction and management
Two review authors independently extracted the data according to
the guidelines proposed by Higgins 2011b. If required, we con-
tacted authors of individual studies for additional information.We
used a standardised data extraction form containing the following
items:
• General information: author; title; source; publication date;
country; language; duplicate publications.
• Quality assessment (’Risk of bias’ assessment): sequence
generation; allocation concealment; blinding (participants,
personnel, outcome assessors); incomplete outcome data;
selective outcome reporting; other potential sources of bias.
• Study characteristics: trial design; aims; setting and dates;
source of participants; inclusion and exclusion criteria;
comparability of groups; subgroup analysis; statistical methods;
power calculations; treatment cross-overs; compliance with
assigned treatment; length of follow-up; time point of
randomisation.
• Participant characteristics: age; diagnosis; stage of disease;
prior treatments; number of participants recruited, allocated, and
evaluated; participants lost to follow-up; noticeable differences in
risk factors for developing FN.
• Interventions: duration; type; dose and timing of GM-CSF,
G-CSF, antibiotics, and other infection prophylaxes (e.g.
antimycotics); concomitant treatment (setting, duration, type of
chemotherapy); and supportive care (e.g. type of empirical
antibiotic therapy).
• Outcomes: all cause mortality; infection-related mortality;
microbiologically or clinically documented infections, or both;
severe infections; QoL; frequency of FN; adverse events.
Assessment of risk of bias in included studies
Two review authors (NS and OB) independently assessed the risk
of bias for each study using the following criteria outlined inChap-
ter 8 of the Cochrane Handbook for Systematic Reviews of Interven-
tions(Higgins 2011a).
• Sequence generation
• Allocation concealment
• Blinding (participants, personnel, outcome assessors)
• Incomplete outcome data
• Selective outcome reporting
• Other potential sources of bias
We made a judgement for every criterion, using one of three cat-
egories.
1. ’Low risk’: if the criterion was adequately fulfilled in the
study, i.e. the study was at a low risk of bias for the given
criterion.
2. ’High risk’: if the criterion was not fulfilled in the study, i.e.
the study was at high risk of bias for the given criterion.
3. ’Unclear’: if the study report did not provide sufficient
information to allow for a judgement of ’Yes’ or ’No’, or if the
risk of bias was unknown for one of the criteria listed above.
Measures of treatment effect
We used intention-to-treat data. For binary outcomes, we calcu-
lated risk ratios (RRs) with 95% confidence intervals (CIs) for
each comparison. We did not identify or extract time-to-event or
continuous outcomes.
Unit of analysis issues
We evaluated the number of patients with events rather than num-
ber of episodes, as the second one could be biased (e.g. a patient
with one episode of febrile neutropenia is at increased risk to have
a second episode of febrile neutropenia).
Dealing with missing data
As suggested in Chapter 16 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011b), there were many po-
tential sources of missing data that had to be taken into account:
at the study level, outcome level, and summary data level. It is
important to distinguish between ’missing at random’ and ’not
missing at random’. As we only identified one trial without miss-
ing data, we did not contact the original investigators.
Assessment of heterogeneity
As we only found two trials, which we did not meta-analyse, we
did not assess heterogeneity of treatment effects between trials.
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Assessment of reporting biases
In meta-analyses with at least 10 trials included for one outcome,
we would have explored potential publication bias by generating a
funnel plot and statistically testing this by using a linear regression
test (Sterne 2011). We would have considered a P value of less
than 0.1 to be significant for this test. However, as we analysed
two trials only, we did not generate a funnel plot.
Data synthesis
As we only identified one trial for each comparison, we could
not pool data. However, to analyse data for individual studies we
entered data into Review Manager (RevMan) 5.3.
Moreoever, we created ’Summary of findings’ tables for each com-
parison on absolute risks in each group with the help of the
GRADE approach, and will use it to summarise the evidence of
all cause mortality, infection-related mortality, quality of life, in-
cidence of febrile neutropenia, incidence of severe infections and
adverse events.
Subgroup analysis and investigation of heterogeneity
We had considered performing subgroup analyses using the fol-
lowing characteristics:
• Different types of underlying malignant disease;
• Different baseline risk for febrile neutropenia or infection;
• Study setting (in-patients or out-patients);
• Different type of treatment (e.g. haematologic stem cell
transplantation versus standard chemotherapy);
• Different types of G-CSFs used;
• Age (<18 versus ≥ 18 years); and
• According to whether regimens included antimycotic
prophylaxis.
However, as we had insufficient data to meta-analyse, we could
not perform these analyses.
Sensitivity analysis
We had considered performing sensitivity analyses using the fol-
lowing quality criteria:
• Quality components with regard to low and high risk of
bias;
• Fixed-effect modelling versus random-effects modelling;
• Duration of study; and
• full-text publication versus abstract publication only.
Again, as we identified only two trials, which were too heteroge-
nous to pool, we could not perform these analyses.
R E S U L T S
Description of studies
Results of the search
The literature search was designed to find all relevant articles
where G-CSFs, GM-CSFs, or antibiotics were used as prophylac-
tic agents. For this update, we set up a new search covering all
time periods, i.e. after removing duplicates, we screened titles and
abstracts of 11,785 references and excluded 11,696 at the initial
stage. We assessed the full text of the remaining 89 references and
excluded 87 references with reasons (see Excluded studies). As we
identified no new trial fitting the inclusion criteria for this review
update, we included the two already known trials in this review.
See Figure 1 for study flow diagram.
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Figure 1. Study flow diagram.
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Included studies
Two studies fulfilled the inclusion criteria of this review. One study
involved adults with breast cancer receiving high-dose chemother-
apy, and compared prophylaxis for at least six cycles (Schroder
1999). The other trial evaluated patients with small-cell lung can-
cer receiving accelerated chemotherapy (Sculier 2001). For more
details see Characteristics of included studies.
Design
Schroder 1999 was an open-label randomised (1:1) study. Sculier
2001 was a three-arm trial, two arms of which could be analysed
in this review. The third arm evaluated standard chemotherapy
without any infectious prophylaxis.
Sample sizes
Schroder 1999 included 40 patients, 18 in the G-CSF prophylaxis
arm and 22 in the antibiotics arm. Sculier 2001 included 243
patients, 233 of whomwere eligible. However, 78 of these patients
received an intervention not applicable for this review, therefore
155 patients were analysed in this review.
Locations
Location is not reported by Schroder 1999, the Sculier 2001 trial
took place in several European countries.
Participants
Schroder 1999 randomised chemotherapy-naive patients with
breast cancer who received three, three-week courses of intra-
venous cyclophosphamide (1500 mg/m²), epirubicin (80mg/m²),
and5-fluouracil (1500or 1000mg/m²) given on day one; followed
by three cycles of intravenous cyclophosphamide (1500 mg/m²),
5-fluouracil (600 mg/m²) on day one and intravenous methotrex-
ate (1500 mg/m²) on day two. Sculier 2001 included patients with
small-cell lung cancer receiving six courses of EVI (epirubicin 90
mg/m², vindesine 3 mg/m² and ifosfamide 5 g/m²) every 14 days.
Interventions
In the G-CSF arm in the Schroder 1999 trial, patients received
263 µg subcutaneous of G-CSF (lenograstim) on days 3 through
to day 12 of each cycle. Patients in the antibiotics arm received
two oral prophylactic agents, a combination of ciprofloxacin (250
mg twice daily) and amphotericin B (500 mg four times per day)
on days 3 through to day 17 of each cycle, without blinding of
the study participants. Patients in the Sculier 2001 study received
either GM-CSF as a daily subcutaneous dose of 5 µg/kg, from day
3 through to day 13 or until the neutrophil count reached≥ 4000
mm³ after nadir, or cotrimoxazole (160 mg trimethoprim plus
800 mg sulfamethoxazole). This was administered orally every 12
hours from day three until the end of the courses of chemotherapy.
Outcomes
Schroder 1999 evaluated infection-related mortality, episodes of
hospitalisation for febrile neutropenia, duration of hospitalisation
for febrile neutropenia, grade IV leucopenia, and analysed costs
of prophylaxis. Sculier 2001 assessed overall survival, tumour re-
sponse, absolute and relative dose intensity, incidence of infections
and severe infection, and adverse events. None of the trials evalu-
ated quality of life.
Conflict of interest
Funding not reported.
Excluded studies
We excluded 87 trials with reasons (one trial included two com-
parisons (Tjan-Heijnen 2003):
• 14 trials compared antibiotics to placebo or no further
treatment (Attal 1991; Carlson 1997; Cullen 2005; Dickgreber
2009; Karp 1986; Lamy 1993; Lee 2002; Petersen 1988; Pignon
1990; Rafecas 1989; Schuette 2011; Talbot 1993; Tjan-Heijnen
2003; Yamada 1993).
• 46 trials compared antibiotics and G-CSF or GM-CSF to
antibiotics only (Aarts 2013; Alonzo 2002; Altman 1996;
Ardizzoni 1994; Bishop 2000; Bradstock 2001; Burton 2006;
Clarke 1999; Dibenedetto 1995; Ernst 2008; Faber 2006; Garcia
2000; Garcia-Saenz 2002; Geissler 1997; Gonzalez-Vicent 2004;
Greenberg 1996; Gulati 1992; Heath 2003; Hecht 2010; Heil
1997; Joshi 2003; Ladenstein 2010; Lee 1998; Lehrnbecher
2007; Little 2002; Maiche 1993; McQuaker 1997; Michel 2000;
Miles 1994; Nemunaitis 1995; Nolan 2007; Ojeda 1999;
Ottmann 1995; Pettengell 1992; Piccirillo 1999; Przepiorka
2001; Pui 1997; Schmitz 2004; Spitzer 1994; Stahel 1994;
Timmer-Bonte 2005; Trigg 2000; Welte 1996; Witz 1998; Yau
1996; Zinzani 1997a).
• 7 trials compared antibiotics and G-CSF to G-CSF only
(Eleutherakis-Papaiakovou 2010; Feng 2014; Kim 2005; Lalami
2004; Lee 1998; Suh 2008; Tjan-Heijnen 2003).
• 21 trials compared G-CSF to placebo or no further
treatment (Bennett 2001; Björkholm 1999; Brugger 2009;
Chevallier 1995; Crawford 1997; Doorduijn 2005; Dunlop
1996; Fridrik 1997; Godwin 1998; Hartmann 1997;
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Holowiecki 2002; Kosaka 2015; Larson 1998; Michon 1998;
Osby 2003; Patte 2002; Romieu 2007; Seymour 1995;
Trillet-Lenoir 1993; Veyret 2006; Vogel 2005).
Risk of bias in included studies
See Figure 2 and Figure 3 for risk of bias summary.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
13Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving
myelotoxic chemotherapy (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Both trials were described as randomised, but the randomisation
procedure was not reported. Therefore, we judged the risk of se-
lection bias as unclear.
Blinding
There was no blinding of the participants or personnel due to the
use of either an oral antibiotic or subcutaneous injections of GM-
CSF; no information was given about whether or not the assessors
were blinded. Therefore we judged potential risk of performance
bias as high and of detection bias as unclear.
Incomplete outcome data
As 23 courses from seven patients from the antibiotics group,
who switched to rhG-CSF, were not included in the analysis by
Schroder 1999, we judged the risk of attrition bias as high in this
trial. All patients in the Sculier 2001 trial were evaluated as ran-
domised, reasons for ten patients not being eligible after randomi-
sation were given. Therefore, we judged risk of attrition bias for
this trial as low.
Selective reporting
As we did not identify study protocols; it is unclear if all the
planned outcomes are reported. We judged the risk of reporting
bias as unclear.
Other potential sources of bias
As no other potential source of bias was reported, we judged this
bias as “unclear”.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
Comparison 1: G-CSF versus antibiotics
Overall survival
Not reported by Schroder 1999.
All cause mortality (including infection-related, treatment-
related, or on-trial mortality)
Not reported by Schroder 1999.
Infection-related mortality
Infection-related mortality was the same in both groups of the
Schroder 1999 trial: no patient died of infectious causes during
the 18-week duration of the trial.
Microbiologically or clinically documented infections
Not reported.
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Incidence of severe infections
Not reported
Quality of life (QoL)
Not reported.
Incidence of febrile neutropenia (FN)
Schroder 1999 reported febrile neutropenia in 7/18 patients re-
ceiving G-CSF and in 7/22 patients receiving ciprofloxacin and
amphotericin B (relative risk (RR) 1.22; 95% confidence interval
(CI) 0.53 to 2.84).
Adverse events
Not reported.
Comparison 2: GM-CSF versus antibiotics
Overall survival
There was no evidence of a difference in median survival time,
with 264 (95% CI 220 to 308) days for patients in the GM-CSF
arm and 264 (95% CI 223 to 305 days) in the antibiotics arm
(Sculier 2001). Two-year survival times were 6% (0 to 12%) in
both arms.
All cause mortality (including infection-related, treatment-
related, or on-trial mortality)
Therewere four toxic deaths in theGM-CSFarm (5.1%) and three
in the antibiotics arm (3.8%), without evidence for a difference
(RR 1.32; 95% CI 0.30 to 5.69; P = 0.71).
Infection-related mortality
This outcome was not reported in Sculier 2001.
Microbiologically or clinically documented infections
There were 22 grade III or IV infections (28%) in the GM-CSF
arm in the Sculier 2001 trial and 14 infections (18%) in the an-
tibiotics arm, without any evidence of a difference (RR 1.55; 95%
CI 0.86 to 2.80; P = 0.15).
Incidence of severe infections
There were 5 episodes out of 360 cycles (1.3%) of grade IV infec-
tions in the GM-CSF arm and 3 episodes out of 334 cycles in the
cotrimoxazole arm (0.8%), without evidence of a difference (RR
1.55; 95% CI 0.37 to 6.42; P = 0.55).
Quality of life (QoL)
Not reported.
Incidence of febrile neutropenia (FN)
Not reported.
Adverse events
There was no significant difference between the two arms for non-
haematological toxicities like diarrhoea, stomatitis, infections,
neurologic, respiratory or cardiac adverse events. Grade III and IV
thrombopenia occurred significantly more frequently in the GM-
CSF arm (60.8%) compared to the antibiotics arm (28.9%); with
a RR 2.10; 95% CI 1.41 to 3.12; P = 0.0002.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
GM-CSF compared with antibiotics for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
Patient or population: cancer patients receiving myelotoxic chemotherapy
Intervention: GM-CSF
Comparison: antibiotics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Antibiotics GM-CSF
All cause mortality see comment 115
(1 RCT)
⊕⊕©©1
low
Two-year survival times
were 6% (0 to 12%) in
both arms
Infection-related mortality see comment not reported
Quality of life see comment not reported
Incidence of febrile neu-
tropenia
see comment not reported
Incidence of severe infec-
tions
(Grade III or IV)
182 per 1000 282 per 1000
(156 to 509)
RR 1.55
(0.86 to 2.80)
115
(1 RCT)
⊕⊕©©1
low
not reported
Adverse events
Toxic deaths
39 per 1000 51 per 1000
(12 to 222)
RR 1.32
(0.30 to 5.69)
115
(1 RCT)
⊕⊕©©1
low
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 due to the low number of very low number of events, the result is highly imprecise (downgraded by 2 points)
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D I S C U S S I O N
Summary of main results
The striking finding of this review is that there is only one very
small study comparing granulocyte colony-stimulating factors (G-
CSF) to antibiotics for infection prophylaxis in cancer patients
receiving myelosuppressive chemotherapy, and one trial with 155
patients evaluating granulocyte macrophage colony-stimulating
factors (GM-CSF) versus antibiotics. The trial evaluating G-CSF
did not report all cause mortality, incidence of documented or
severe infections, quality of life, or adverse events. We did not find
evidence of a difference in infection-related mortality (none of the
40 included patients died because of infection), or in incidence of
febrile neutropenia.
The trial that evaluated GM-CSF reported overall survival, toxic
deaths, infections and severe infections and non-haematological
adverse events, without any evidence of a difference between the
GM-CSF arm and the antibiotics arm. Patients in the antibiotics
arm had fewer thrombopenic adverse events. Quality of life was
not reported.
Overall completeness and applicability of
evidence
As only two small trials were identified, it is not possible to come
to a final conclusion regarding the best prophylactic regimen in
cancer patients at risk of neutropenia. Therefore, this clinically
important question remains unanswered. Moreover, the trial as-
sessing G-CSF evaluated only a few of the outcomes of interest
(incidence of febrile neutropenia and infection-related mortality),
but all cause mortality, incidence of documented or severe infec-
tions, quality of life, and adverse events were not assessed.
The trial evaluating GM-CSF versus antibiotics reported more of
the outcomes of interest (overall survival, toxic deaths, infections
and severe infections and adverse events), however, due to the small
sample size, there was no evidence of a difference, except for the
adverse event, thrombocytopenia.
The 41 trials that were excluded because they evaluated the influ-
ence of the combination of GM-CSF and antibiotics compared
to GM-CSF or antibiotics only, underline the huge imbalance be-
tween the number of direct comparisons of the two drugs we eval-
uated in this review, and the number of trials that were conducted
in this field.
Quality of the evidence
The risk of bias in Schroder 1999 was high, as this trial was not
blinded and not all patients of the included 40 patients were anal-
ysed as randomised (seven of 22 patients from the antibiotics arm
crossed-over to G-CSF and were excluded from analysis). The risk
of bias for Sculier 2001 could be considered to be moderate, as risk
of performance bias was high, but risk of selection and attrition
bias was low.
As only two trials could be included in this review, one evaluating
G-CSF, the other evaluating GM-CSF, no meta-analysis was pos-
sible.The trial evaluating G-CSF reported infection-related mor-
tality and incidence of febrile neutropenia. We judged the quality
of evidence for both outcomes to be very low, due to the small
number of events, which lead to high imprecision (downgraded
by two levels), and the high risk of bias (downgraded by one level).
The trial that analysed GM-CSF versus antibiotics reported over-
all survival, toxic deaths, infections, severe infections and adverse
events. Because of the very small number of patients included, we
downgraded overall quality of the evidence for all outcomes by
two levels (high imprecision). As risk of bias was moderate in this
trial, we did not downgrade the quality of evidence for this reason.
Therefore, overall quality for all the outcomes mentioned above
was considered to be low.
Potential biases in the review process
To prevent bias within the review, we considered only RCTs and
performed all relevant processes in duplicate. We developed a sen-
sitive search strategy, and searched all relevant data from interna-
tional cancer congresses by hand tominimise potential publication
bias. We are not aware of any obvious deficiencies in our review
process. The small number of trials included in this review could
lead to publication bias as a funnel plot could not be generated.
Agreements and disagreements with other
studies or reviews
One comprehensive meta-analysis of GM-CSF versus control in-
cludes 148 trials with more than 16,000 patients (Sung 2007).
However, in this publication it is not reported how many pa-
tients received additional antibiotics, and how many patients re-
ceived either G-CSF or GM-CSF. Similarly, the most comprehen-
sive antibiotics versus control meta-analysis includes 49 trials with
more than 6000 patients (for the outcome all cause mortality;
Gafter-Gvili 2005). The low number of trials directly comparing
antibiotics to G-CSFs is surprising, considering the higher cost
of GM-CSFs compared to standard antibiotics. However, a high
number of trials comparing GM-CSFs to control received fund-
ing from pharmaceutical companies that produce GM-CSFs. As
there are only two small trials directly comparing G-CSF or GM-
CSF versus antibiotics, no final conclusion on the best prophylac-
tic regimen is possible. Clearly, more trials with larger numbers of
patients are required to answer this question, in particular, with
regard to early all cause and infection-related mortality. In addi-
tion, GM-CSF is no longer commercially available for infection
prophylaxis in several European countries; it is licensed instead for
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mobilisation of stem cells or after autologous or allogeneic stem
cell transplantation (Smith 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient direct evidence from randomised controlled
trials to recommend one prophylaxis (G-CSFs, GM-CSFs, or an-
tibiotics) over the other for cancer patients receiving myelotoxic
chemotherapy.
Implications for research
Large high quality trials comparing antibiotic prophylaxis to in-
fection prophylaxis using G-CSFs or GM-CSFs are necessary in
a wide range of cancer patients, to evaluate clinically important
outcomes, like all cause and infection-related mortality, incidence
of febrile neutropenia, quality of life and adverse events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Schroder 1999
Methods Randomisation
• 1:1 ratio
• Intervention arm: G-CSF for prevention of infection
• Control arm: ciprofloxacin and amphotericin
Recruitment Period
• Not reported
Median follow-up time
• Not reported
Participants 40 patients randomised
• 18 patients G-CSF
• 22 patients antibiotics
Inclusion criteria
• Patients with metastatic breast cancer
• Age ≤ 65 years
• Chemotherapy-naive
Mean age in years
• G-CSF arm: 39 years (range: 28 to 50)
• Antibiotics arm: 42 years (range: 29 to 51)
Metastases
• G-CSF arm:
◦ 8 single metastases
◦ 10 multiple metastases
• Antibiotics arm
◦ 14 single metastases
◦ 8 multiple metastases
Country
• Not reported
Interventions All patients
• 3 courses of IV cyclophosphamide (1500 mg/m²), epirubicin (80 mg/m²) and 5-
fluorouracil (5-FU; 1500 or 1000 mg/m²) on day 1
• 3 courses of IV cyclophosphamide (1500 mg/m²) and 5-FU (600mg/m²) on day
1 and IV methotrexate (1500 mg/m²) on day 2
G-CSF arm
• 263 µg subcutaneously on days 3 to 12
Antibiotics arm
• Oral ciprofloxacin 2 x 250 mg daily, and oral amphotericin B suspension 100 mg/
mL, 4 x 5 mL daily; both on days 3 to 17
Outcomes • Episodes of hospitalisation for febrile neutropenia
• Duration of hospitalisation for febrile neutropenia
• Grade IV leucopenia
• Cost analyses
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Schroder 1999 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Before chemotherapy, patients were ran-
domized to group I or II.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial (subcutaneous injection of
G-CSF versus oral antibiotics)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk “Not included in the analyses were 23
courses from seven patients from group II
(antibiotics), who switched to rhG-CSF.Of
these seven patients, three patients stopped,
because of disease progression or death
from the disease, after having received a
total of nine courses; therefore 11 more
courses were not administered and not in-
cluded in the analyses.”
Selective reporting (reporting bias) Unclear risk No study protocol identified, therefore un-
clear, if all the planned outcomes are re-
ported
Other bias Unclear risk Not reported
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Sculier 2001
Methods Randomisation
• 1:1:1 ratio
• Standard chemotherapy arm (6 courses of EVI (epirubicin 90 mg/m² , vindesine
3 mg/m² and ifosfamide 5 g/m² ; all drugs given IV on day 1); no infection prophylaxis
given (therefore not evaluated in this review)
• Intervention arm: accelerated chemotherapy (the same as above, given every 14
days) and GM-CSF for prevention of infection
• Control arm: accelerated chemotherapy (the same as above, given every 14 days)
and cotrimoxazole prophylaxis
Recruitment Period
• April 1993 to April 2000
Median follow-up time
• Not reported
Participants 243 patients randomised, 233 eligible
• 78 standard arm (not evaluated in this review)
• 78 patients GM-CSF
• 77 patients antibiotics
Inclusion criteria
• Patients with small-cell lung cancer and extensive disease (with metastases or as a
locoregional disease that could not be locally treated in a single radiotherapy field)
• Age ≤ 75 years
• Patients should not have had prior therapy (radiotherapy, chemotherapy, surgery)
Mean age in years
• GM-CSF arm: 64 years (range: 35 to 74)
• Antibiotics arm: 61 years (range: 37 to 74)
Stage
• GM-CSF arm:
◦ Stage III: 7 patients
◦ Stage IV: 71 patients
• Antibiotics arm
◦ Stage III: 7 patients
◦ Stage IV: 70 patients
Brain metastases
• GM-CSF arm:
◦ 14 patients
• Antibiotics arm
◦ 17 patients
Countries
• Several countries in Europe
Interventions All patients
• 6 courses of EVI (epirubicin 90 mg/m² , vindesine 3 mg/m² and ifosfamide 5 g/
m² ; all drugs given IV on day 1, in the accelerated arms every 14 days
GM-CSF arm
• GM-CSF was given, as a daily subcutaneous dose of 5 µg/kg, from day 3 through
day 13, or until neutrophil count reached ≥ 4000 mm³ after nadir.
Antibiotics arm
• Cotrimoxazole (160 mg trimethoprim plus 800 mg sulfamethoxazole) was
administered orally every 12 hours from day 3 until the end of the course of
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Sculier 2001 (Continued)
chemotherapy
Outcomes • Overall survival
• Tumour response
• Absolute and relative dose intensity
• Incidence of infections and severe infection
• Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “eligible patients were randomised”
Allocation concealment (selection bias) Unclear risk not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial (subcutaneous injection of
GM-CSF versus oral antibiotics)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “In the 233 eligible patients, 14 were
nonassessable for response (2 in arm A, 6
in arm B, and 6 in arm C) for the following
reasons: too long delay between 2 courses
of chemotherapy (1), early death unrelated
to cancer or treatment complications (9),
protocol violation (2), death prior to start-
ing treatment (1), nowork-up at evaluation
(1)”
Selective reporting (reporting bias) Unclear risk No study protocol identified, therefore un-
clear if all the planned outcomes are re-
ported
Other bias Unclear risk Not reported
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aarts 2013 Comparison of G-CSF plus antibiotics versus antibiotics alone
Alonzo 2002 Comparison of G-CSF plus antibiotics versus antibiotics alone
Altman 1996 Comparison of G-CSF plus antibiotics versus antibiotics alone
Ardizzoni 1994 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Attal 1991 Comparison of antibiotics versus placebo
Bennett 2001 Comparison of G-CSF versus placebo
Bishop 2000 Comparison of G-CSF plus antibiotics versus antibiotics alone
Björkholm 1999 Comparison of G-CSF versus placebo
Bradstock 2001 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Brugger 2009 Comparison of G-CSF versus placebo
Burton 2006 Comparison of G-CSF plus antibiotics versus antibiotics alone
Carlson 1997 Comparison of antibiotics versus placebo
Chevallier 1995 Comparison of G-CSF versus placebo
Clarke 1999 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Crawford 1997 Comparison of G-CSF versus placebo
Cullen 2005 Comparison of antibiotics versus placebo
Dibenedetto 1995 Comparison of G-CSF plus antibiotics versus antibiotics alone
Dickgreber 2009 Comparison of antibiotics versus placebo
Doorduijn 2005 Comparison of G-CSF versus placebo
Dunlop 1996 Comparison of G-CSF versus placebo
Eleutherakis-Papaiakovou 2010 Comparison of G-CSF plus antibiotics versus G-CSF alone
Ernst 2008 Comparison of G-CSF plus antibiotics versus antibiotics alone
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(Continued)
Faber 2006 Comparison of G-CSF plus antibiotics versus antibiotics alone
Feng 2014 Comparison of G-CSF plus antibiotics versus G-CSF alone
Fridrik 1997 Comparison of G-CSF versus placebo
Garcia 2000 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Garcia-Saenz 2002 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Geissler 1997 Comparison of G-CSF plus antibiotics versus antibiotics alone
Godwin 1998 Comparison of G-CSF versus placebo
Gonzalez-Vicent 2004 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Greenberg 1996 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Gulati 1992 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Hartmann 1997 Comparison of G-CSF versus placebo
Heath 2003 Comparison of G-CSF plus antibiotics versus antibiotics alone
Hecht 2010 Comparison of G-CSF plus antibiotics versus antibiotics alone
Heil 1997 Comparison of G-CSF plus antibiotics versus antibiotics alone
Holowiecki 2002 Comparison of G-CSF versus placebo
Jones 1996 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Joshi 2003 Comparison of G-CSF plus antibiotics versus antibiotics alone
Karp 1986 Comparison of antibiotics versus placebo
Kim 2005 Comparison of G-CSF plus antibiotics versus G-CSF alone
Kosaka 2015 Comparison of G-CSF versus placebo
Ladenstein 2010 Comparison of G-CSF plus antibiotics versus antibiotics alone
Lalami 2004 Comparison of GM-CSF plus antibiotics versus GM-CSF alone
Lamy 1993 Comparison of antibiotics versus placebo
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(Continued)
Larson 1998 Comparison of G-CSF versus placebo
Lee 1998 Comparison of G-CSF plus antibiotics versus antibiotics alone
Lee 2002 Comparison of antibiotics versus placebo
Lehrnbecher 2007 Comparison of G-CSF plus antibiotics versus antibiotics alone
Little 2002 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Maiche 1993 Comparison of GM-CSF plus antibiotics versus GM-CSF alone
McQuaker 1997 Comparison of G-CSF plus antibiotics versus antibiotics alone
Michel 2000 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Michon 1998 Comparison of G-CSF versus placebo
Miles 1994 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Nemunaitis 1995 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Nolan 2007 Comparison of G-CSF plus antibiotics versus antibiotics alone
Ojeda 1999 Comparison of G-CSF plus antibiotics versus antibiotics alone
Osby 2003 Comparison of G-CSF versus placebo
Ottmann 1995 Comparison of G-CSF plus antibiotics versus antibiotics alone
Patte 2002 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Petersen 1988 Comparison of antibiotics versus placebo
Pettengell 1992 Comparison of G-CSF plus antibiotics versus antibiotics alone
Piccirillo 1999 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Pignon 1990 Comparison of antibiotics versus placebo
Przepiorka 2001 Comparison of G-CSF plus antibiotics versus antibiotics alone
Pui 1997 Comparison of G-CSF plus antibiotics versus antibiotics alone
Rafecas 1989 Comparison of antibiotics versus placebo
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(Continued)
Romieu 2007 Comparison of G-CSF versus placebo
Schmitz 2004 Comparison of G-CSF plus antibiotics versus antibiotics alone
Schuette 2011 Comparison of antibiotics versus placebo
Seymour 1995 Comparison of G-CSF versus placebo
Spitzer 1994 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Stahel 1994 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Suh 2008 Comparison of G-CSF plus antibiotics versus G-CSF alone
Talbot 1993 Comparison of antibiotics versus placebo
Timmer-Bonte 2005 Comparison of G-CSF plus antibiotics versus antibiotics alone
Tjan-Heijnen 2003 Comparison of G-CSF plus antibiotics versus antibiotics alone
Trigg 2000 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Trillet-Lenoir 1993 Comparison of G-CSF versus placebo
Veyret 2006 Comparison of G-CSF versus placebo
Vogel 2005 Comparison of G-CSF versus placebo
Welte 1996 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Witz 1998 Comparison of GM-CSF plus antibiotics versus antibiotics alone
Yamada 1993 Comparison of antibiotics versus placebo
Yau 1996 Comparison of GM-CSF plus antibiotics versus antibiotics alone
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
January 2008
#1 MeSH descriptor Anti-Bacterial Agents explode all trees
#2 (antibacterial*) OR (anti-bacterial*)
#3 (antibio*)
#4 (antimicrobial*) OR (anti-microbial*) OR (anti-mycobacterial*) OR (antimyocobacterial*) OR (bacteriocid*) OR (selective
NEAR/3 decontaminat*)
#5 MeSH descriptor Antibiotic Prophylaxis explode all trees
#6 MeSH descriptor Quinolones explode all trees
#7 (fluoroquinilones) OR (ciprofloxa*in*) OR (ofloxa*in*) OR (norfloxa*in*) OR (enoxa*in*) OR (pefloxa*in*)
#8 MeSH descriptor Trimethoprim explode all trees
#9 (trimethoprim) OR (sulfamethoxazol*) OR (trimethoprim-sulfamethoxazol*, (trimethoprim NEAR/3 sulfamethoxazol*)) OR
(tmp-smz*)
#10 MeSH descriptor Polymyxins explode all trees
#11 (colistin) OR (nalidixic NEAR/3 acid) OR (polymyxin)
#12 MeSH descriptor Aminoglycosides explode all trees
#13 MeSH descriptor Gentamicins explode all trees
#14 MeSH descriptor Nebramycin explode all trees
#15 MeSH descriptor Neomycin explode all trees
#16 MeSH descriptor Vancomycin explode all trees
#17 (gentami*in) OR (tobramy*in) OR (meomy*in)
#18 MeSH descriptor Roxithromycin explode all trees
#19 MeSH descriptor Rifampin explode all trees
#20 (vancomy*in) OR (roxithromy*in) OR (rifampin*,rifampicin*)
#21 MeSH descriptor beta-Lactams explode all trees
#22 MeSH descriptor Penicillins explode all trees
#23 MeSH descriptor Amoxicillin explode all trees
#24 MeSH descriptor Cephalothin explode all trees
#25 MeSH descriptor Ceftriaxone explode all trees
#26 MeSH descriptor Ticarcillin explode all trees
#27 (beta-lactam*) OR (peni*illin) OR (amoxi*illin*) OR (cephalot*in*,cefalot*in*) OR (ceftriaxone*)
#28 (tica*illin*) OR (framycetin)
#29 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28)
#30 MeSH descriptor Colony-Stimulating Factors explode all trees
#31 MeSH descriptor Colony-Stimulating Factors, Recombinant explode all trees
#32 MeSH descriptor Granulocyte Colony Stimulating Factor, Recombinant explode all trees
#33 MeSH descriptor Granulocyte Colony-Stimulating Factor explode all trees
#34 MeSH descriptor Macrophage Colony-Stimulating Factor explode all trees
#35 MeSH descriptor Granulocyte-Macrophage Colony-Stimulating Factor explode all trees
#36 (rhg*csf*,rhgm*csf*) OR (rmethug*,rhmethug*) OR (rhug*,rhugm*) OR (gcsf*,g-csf*) OR (gm-csf*,gmcsf*)
#37 (granulo*yt* NEAR/3 fa*tor*) OR (ma*rophag* NEAR/5 fa*tor*) OR (csf.ti) OR (filgrastim*) OR (neupogen*)
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#38 (lenograstim*) OR (euprotin*) OR (peg*filgrastim*) OR (neulasta*) OR (leukine)
#39 (molgramostine*) OR (mielogen*) OR (leucomax*) OR (granocyte)
#40 MeSH descriptor Filgrastim explode all trees
#41 (#30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)
#42 MeSH descriptor Leukopenia, this term only
#43 .MeSH descriptor Agranulocytosis explode all trees
#44 (granulocytopen*) OR (agranulocyto*) OR (neutropen*) OR (leu*open*) OR (aplasia, aplastic, aplasion)
#45 (leukocyt* NEAR/5 nadir) OR (neutrophil NEAR/5 nadir)
#46 MeSH descriptor Infection explode all trees
#47 (infect*)
#48 MeSH descriptor Sepsis explode all trees
#49 (septicemia, septicaemia) OR (bacteraem*, bacterem*) OR (fever*) OR (pyrexia) OR (fever NEAR/4 (unknown NEAR/3
origin))
#50 MeSH descriptor Fever explode all trees
#51 MeSH descriptor Fever of Unknown Origin, this term only
#52 (pneumonia) OR (lung inflammation) OR (pulmonary inflammation) OR (pneumonitis)
#53 (#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)
#54 MeSH descriptor Neoplasms by Histologic Type explode all trees
#55 MeSH descriptor Neoplasms by Site explode all trees
#56 (neoplas*) OR (krebs,cancer*) OR (malignan*)
#57 (leukaem*,leukem*) OR (lymphom*) OR (melano*) OR (metastas*) OR (mesothelio*,mesotelio*)
#58 (gliom,glioblastom*) OR (osteo*sarcom*) OR (carcinomatos*) OR (blastom*) OR (neuroblastom*)
#59 MeSH descriptor Pneumonia explode all trees
#60 (#54 OR #55 OR #56 OR #57 OR #58 OR #59)
#61 (#53 OR #59)
#62 (#29 AND #41 AND #61)
December 2015
ID Search
#1 MeSH descriptor: [Anti-Bacterial Agents] explode all trees
#2 (antibacterial* or anti-bacterial*)
#3 antibio*
#4 (antimicrobial* or anti-microbial*)
#5 (anti-Mycobacterial* or antimycobacterial*)
#6 bacteriocid*
#7 (selective* near/3 decontaminat*)
#8 MeSH descriptor: [Antibiotic Prophylaxis] explode all trees
#9 MeSH descriptor: [Quinolones] explode all trees
#10 Fluoroquinolones*
#11 ciprofloxa*in*
#12 ofloxa*in*
#13 norfloxa*in*
#14 Enoxa*in*
#15 pefloxa*in*
#16 MeSH descriptor: [Trimethoprim] explode all trees
#17 trimethoprim*
#18 sulfamethoxazol*
#19 Trimethoprim-Sulfamethoxazol*
#20 tmp-smz*
#21 MeSH descriptor: [Polymyxins] explode all trees
#22 colistin*
#23 (Nalidixic* near/3 acid*)
#24 Polymyxin*
#25 MeSH descriptor: [Aminoglycosides] explode all trees
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#26 MeSH descriptor: [Gentamicins] explode all trees
#27 Gentami*in*
#28 MeSH descriptor: [Nebramycin] explode all trees
#29 Tobramy*in*
#30 MeSH descriptor: [Neomycin] explode all trees
#31 Neomy*in*
#32 MeSH descriptor: [Vancomycin] explode all trees
#33 Vancomy*in*
#34 MeSH descriptor: [Roxithromycin] explode all trees
#35 Roxithromy*in*
#36 MeSH descriptor: [Rifampin] explode all trees
#37 (rifampin* or rifampicin*)
#38 MeSH descriptor: [beta-Lactams] explode all trees
#39 MeSH descriptor: [Penicillins] explode all trees
#40 MeSH descriptor: [Amoxicillin] explode all trees
#41 MeSH descriptor: [Cephalothin] explode all trees
#42 MeSH descriptor: [Ceftriaxone] explode all trees
#43 MeSH descriptor: [Ticarcillin] explode all trees
#44 (beta-lactam* or beta* lactam*)
#45 Peni*illin*
#46 Amoxi*illin*
#47 (Cephalot*in* or cefalot*in*)
#48 Ceftriaxone*
#49 Ticar*illin*
#50 framycetin*
#51 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38
or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50
#52 MeSH descriptor: [Colony-Stimulating Factors] explode all trees
#53 MeSH descriptor: [Granulocyte Colony-Stimulating Factor] explode all trees
#54 MeSH descriptor: [Granulocyte-Macrophage Colony-Stimulating Factor] explode all trees
#55 MeSH descriptor: [Macrophage Colony-Stimulating Factor] explode all trees
#56 RHG*CSF* or RH-G*CSF* or RHGM*CSF* or RH-GM*CSF*
#57 RMETHUG* or RHMETHUG* or R-METHUG* or RH-METHUG*
#58 RHUG* or RHUGM*
#59 GCSF* or G-CSF*
#60 GM-CSF* or GMCSF*
#61 GRANULO*YT* near/3 FA*TOR*
#62 MA*ROPHAG* near/5 FA*TOR*
#63 FILGRASTIM*
#64 neupogen*
#65 religrast*
#66 nugraf*
#67 LENOGRASTIM*
#68 Granocyte*
#69 Euprotin*
#70 PEG*FILGRASTIM*
#71 Neulasta*
#72 LEUKINE*
#73 sagramostim*
#74 MOLGRAMOSTIN*
#75 macrogen*
#76 Mielogen*
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#77 Leucomax*
#78 nartograstim*
#79 pegnartograstim*
#80 ecogramostim*
#81 regramostim*
#82 leridistim*
#83 #52 or #53 or #54 or #55 or #56 or #57 or #58 or #60 or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 or #69 or #70
or #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82
#84 biograstim*
#85 ratiograstim*
#86 XM02*
#87 immunex*
#88 granulokin*
#89 nivestim*
#90 tevagrastim*
#91 zarzio*
#92 #84 or #85 or #86 or #87 or #88 or #89 or #90 or #91
#93 #83 or #92
#94 #51 or #93
#95 MeSH descriptor: [Neoplasms by Histologic Type] explode all trees
#96 MeSH descriptor: [Neoplasms by Site] explode all trees
#97 neoplas*
#98 tumor* or tumour*
#99 (Krebs* or cancer*)
#100 malignan*
#101 (carcino* or karzino*)
#102 karzinom*
#103 sarcom*
#104 leukem* or leukaem*
#105 lymphom*
#106 melano*
#107 metastas*
#108 (mesothelio* or mesotelio*)
#109 carcinomatos*
#110 osteo*sarcom*
#111 (blastom* or neuroblastom*)
#112 carcinomatos*
#113 (gliom* or glioblastom*)
#114 osteo*sarcom*
#115 (blastom* or neuroblastom*)
#116 #95 or #96 or #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #108 or #112 or #113 or #114
or #115
#117 #94 and #116
#118 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #17 or #18 or #19 or #20 or #
22 or #23 or #24 or #25 or #27 or #28 or #29 or #31 or #33 or #35 or #37 or #43 or #44 or #45 or #46 or #47 or #48 or #50
#119 #118 or #93
#120 #116 and #119 Publication Date from 1985 to 2014, in Trials
#121 #118 and #93
#122 #116 and #121 Publication Date from 1985 to 2015
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Appendix 2. MEDLINE search strategy
From 1980 to 20 January 2008
1 exp ANTI-BACTERIAL AGENTS/
2 (antibacterial$ or anti-bacterial$).tw,kf,ot.
3 antibio$.tw,kf,ot.
4 (antimicrobial$ or anti-microbial$).tw,kf,ot.
5 (anti-mycobacterial$ or antimycobacterial$).tw,kf,ot.
6 bacteriocid$.tw,kf,ot.
7 (selective$ adj3 decontaminat$).tw,kf,ot.
8 ANTIBIOTIC PROPHYLAXIS/
9 exp QUINOLONE/
10 fluoroquinolones$.tw,kf,ot.
11 ciprofloxa#in$.tw,kf,ot.
12 ofloxa#in$.tw,kf,ot.
13 norfloxa#in$.tw,kf,ot.
14 enoxa#in$.tw,kf,ot.
15 pefloxa#in$.tw,kf,ot.
16 exp TRIMETHOPRIM/
17 trimethoprim$.tw,kf,ot.
18 sulfamethoxazol$.tw,kf,ot.
19 trimethoprim-sulfamethoxazol$.tw,kf,ot.
20 tmp-smz$.tw,kf,ot.
21 exp POLYMYXINS/
22 colistin$.tw,kf,ot.
23 (nalidixic$ adj3 acid$).tw,kf,ot.
24 polymyxin$.tw,kf,ot.
25 AMINOGLYCOSIDES/
26 GENTAMICINS/
27 gentami#in$.tw,kf,ot.
28 exp NEBRAMYCIN/
29 tobramy#in$.tw,kf,ot.
30 NEOMYCIN/
31 neomy#in$.tw,kf,ot.
32 VANCOMYCIN/.
33 vancomy#in$.tw,kf,ot.
34 ROXITHROMYCIN/
35 roxithromy#in$.tw,kf,ot.
36 RIFAMPIN/
37 (rifampin$ or rifampicin$).tw,kf,ot.
38 BETA-LACTAMS/
39 beta-lactam$.tw,kf,ot.
40 PENICILLINS/
41 peni#illin$.tw,kf,ot.
42 AMOXICILLIN/
43 amoxi#illin$.tw,kf,ot.
44 CEPHALOTHIN/
45 (cephalot?in$ or cefalot?in$).tw,kf,ot.
46 CEFTRIAXONE/
47 ceftriaxone$.tw,kf,ot.
48 TICARCILLIN/
49 ticar#illin$.tw,kf,ot.
50 framycetin$.tw,kf,ot.
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51 or/1-50
52 COLONY-STIMULATING FACTORS/
53 exp COLONY-STIMULATING FACTORS, RECOMBINANT/
54 exp GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT/
55 exp GRANULOCYTE COLONY-STIMULATING FACTOR/
56 exp GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/
57 MACROPHAGE COLONY-STIMULATING FACTOR/
58 (rhg?csf$ or rhgm?csf$).tw,kf,ot.
59 (rmethug$ or rhmethug$).tw,kf,ot.
60 (rhug$ or rhugm$).tw,kf,ot.
61 (gcsf$ or g-csf$).tw,kf,ot.
62 (gm-csf$ or gmcsf$).tw,kf,ot.
63 (granulo?yt$ adj3 fa#tor$).tw,kf,ot.
64 (ma#rophag$ adj5 fa#tor$).tw,kf,ot.
65 csf.ti.
66 FILGRASTIM$.tw,hw,nm,kf.
67 NEUPOGEN$.tw,hw,nm,kf.
68 LENOGRASTIM$.tw,hw,nm,kf.
69 GRANOCYTE$.tw,hw,nm,kf.
70 EUPROTIN$.tw,hw,nm,kf.
71 PEG?FILGRASTIM$.tw,hw,nm,kf.
72 NEULASTA$.tw,hw,nm,kf.
73 LEUKINE$.tw,hw,nm,kf.
74 MOLGRAMOSTIN$.tw,hw,nm,kf.
75 Mielogen$.tw,kf,ot.
76 LEUCOMAX$.tw,hw,nm,kf.
77 or/52-76
78 51 or 77
79 *LEUKOPENIA/
80 exp AGRANULOCYTOSIS/
81 granulocytopen$.tw,kf,ot.
82 agranulocyto$.tw,kf,ot.
83 neutropen$.tw,kf,ot.
84 leu#open$.tw,kf,ot.
85 (aplasia or aplastic or aplasion).tw,kf,ot.
86 (leukocyt$ adj5 nadir).tw,ot.
87 (neutrophil$ adj5 nadir).tw,ot.
88 INFECTION/
89 infect$.tw,kf,ot.
90 SEPSIS/
91 (septicem$ or septicaem$).tw,kf,ot.
92 (bacteraem$ or bacterem$).tw,kf,ot.
93 FEVER/
94 fever$.tw,kf,ot.
95 pyrexia$.tw,kf,ot.
96 “Fever of Unknown Origin”/
97 (fever adj4 (unknown adj3 origin)).tw,kf,ot.
98 PNEUMONIA/
99 (lung$ or pulmon$) and inflammation$).tw,kf,ot.
100 pneumonit$.tw,kf,ot.
101 engraftment$.tw,kf,ot.
102 (neutrophil$ adj3 recover$).tw,kf,ot.
103 (haematolog$ adj3 recover$).tw,kf,ot.
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104 (hematolog$ adj3 recover$).tw,kf,ot.
105 or/79-104
106 exp NEOPLASMS BY HISTOLOGIC TYPE/
107 exp NEOPLASMS BY SITE/
108 neoplas$.tw,kf,ot.
109 tumo?r$.tw,kf,ot.
110 (krebs$ or cancer$).tw,kf,ot.
111 malignan$.tw,kf,ot.
112 (carcino$ or karzino$).tw,kf,ot.
113 karzinom$.tw,kf,ot.
114 sarcom$.tw,kf,ot.
115 leuk#?m$.tw,kf,ot.
116 lymphom$.tw,kf,ot.
117 melano$.tw,kf,ot.
118 metastas$.tw,kf,ot.
119 (mesothelio$ or mesotelio$).tw,kf,ot.
120 carcinomatos$.tw,kf,ot.
121 (gliom$ or glioblastom$).tw,kf,ot.
122 osteo?sarcom$.tw,kf,ot.
123 (blastom$ or neuroblastom$).tw,kf,ot.
124 or/106-123
125 105 and 124
126 78 and 125
127 randomized controlled trial.pt.
128 controlled clinical trial.pt.
129 RANDOMIZED CONTROLLED TRIALS/
130 RANDOM ALLOCATION/
131 DOUBLE BLIND METHOD/
132 SINGLE BLIND METHOD/
133 or/127-132
134 (ANIMALS not HUMANS)/
135 133 not 134
136 clinical trial.pt.
137 exp CLINICAL TRIALS/
138 (clin$ adj25 trial$).ti,ab.
139 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
140 PLACEBOS/
141 placebo$.ti,ab.
142 random$.ti,ab.
143 RESEARCH DESIGN/
144 or/136-143
145 144 not 134
146 145 not 135
147 COMPARATIVE STUDY/
148 exp EVALUATION STUDIES/
149 FOLLOW UP STUDIES/
150 PROSPECTIVE STUDIES/
151 (control$ or prospectiv$ or volunteer$).ti,ab.
152 or/143-147
153 152 not 134
154 153 not (135 or 146)
155 135 or 146 or 154
156 126 and 155
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Update search January 2008 to 3 December 2015
1 exp ANTI-BACTERIAL AGENTS/
2 (antibacterial$ or anti-bacterial$).tw,kf,ot.
3 Antibio$.tw,kf,ot.
4 (antimicrobial$ or anti-microbial$).tw,kf,ot.
5 (Anti-Mycobacterial$ or antimycobacterial$).tw,kf,ot.
6 Bacteriocid$.tw,kf,ot.
7 (selective adj3 decontaminat$).tw,kf,ot.
8 Antibiotic Prophylaxis/
9 exp QUINOLONE/
10 Fluoroquinolones$.tw,kf,ot.
11 ciprofloxa#in$.tw,kf,ot.
12 ofloxa#in$.tw,kf,ot.
13 norfloxa#in$.tw,kf,ot.
14 Enoxa#in.tw,kf,ot.
15 pefloxa#in$.tw,kf,ot.
16 exp TRIMETHOPRIM/
17 trimethoprim.tw,kf,ot.
18 sulfamethoxazol$.tw,kf,ot.
19 Trimethoprim-Sulfamethoxazol$.tw,kf,ot.
20 tmp-smz$.tw,kf,ot.
21 exp POLYMYXINS/
22 colistin$.tw,kf,ot.
23 (Nalidixic$ adj3 acid$).tw,kf,ot.
24 Polymyxin$.tw,kf,ot.
25 AMINOGLYCOSIDES/
26 GENTAMICINS/
27 Gentami#in$.tw,kf,ot.
28 exp NEBRAMYCIN/
29 Tobramy#in$.tw,kf,ot.
30 NEOMYCIN/
31 Neomy#in$.tw,kf,ot.
32 VANCOMYCIN/
33 Vancomy#in$.tw,kf,ot.
34 ROXITHROMYCIN/
35 Roxithromy#in$.tw,kf,ot.
36 RIFAMPIN/
37 (rifampin$ or rifampicin$).tw,kf,ot.
38 BETA-LACTAMS/
39 PENICILLINS/
40 AMOXICILLIN/
41 CEPHALOTHIN/
42 CEFTRIAXONE/
43 TICARCILLIN/
44 (beta-lactam$ or beta$ lactam$).tw,kf,ot.
45 Peni#illin$.tw,kf,ot.
46 Amoxi#illin$.tw,kf,ot.
47 (Cephalot?in$ or cefalot?in$).tw,kf,ot.
48 Ceftriaxone$.tw,kf,ot.
49 Ticar#illin$.tw,kf,ot.
50 framycetin$.tw,kf,ot.
51 or/1-50
52 COLONY-STIMULATING FACTORS/
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53 exp GRANULOCYTE COLONY-STIMULATING FACTOR/
54 exp GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/
55 MACROPHAGE COLONY-STIMULATING FACTOR/
56 (RHG?CSF$ or RH-G?CSF$ or RHGM?CSF$ or RH-GM?CSF$).tw.
57 (RMETHUG$ or RHMETHUG$ or R-METHUG$ or RH-METHUG$).tw.
58 (RHUG$ or RHUGM$).tw.
59 (GCSF$ or G-CSF$).tw.
60 (GM-CSF$ or GMCSF$).tw.
61 (GRANULO?YT$ adj3 FA#TOR$).tw.
62 (MA#ROPHAG$ adj5 FA#TOR$).tw.
63 CSF.ti.
64 FILGRASTIM$.tw,hw,nm,kf.
65 neupogen$.tw,hw,nm,kf.
66 LENOGRASTIM$.tw,hw,nm,kf.
67 Granocyte.tw,hw,nm,kf.
68 Euprotin.tw,hw,nm,kf.
69 PEG?FILGRASTIM$.tw,hw,nm,kf.
70 Neulasta.tw,hw,nm,kf.
71 LEUKINE.tw,hw,nm,kf.
72 sagramostim$.tw,kf,nm,ot.
73 MOLGRAMOSTIN$.tw,hw,nm,kf.
74 Mielogen$.tw,kf,nm,ot.
75 Leucomax$.tw,hw,nm,kf.
76 nartograstim$.tw,kf,nm,ot.
77 pegnartograstim$.tw,kf,nm,ot.
78 ecogramostim$.tw,kf,nm,ot.
79 regramostim$.tw,kf,nm,ot.
80 leridistim$.tw,kf,ot.
81 or/52-80
82 biograstim$.mp.
83 ratiograstim$.mp.
84 XM02$.mp.
85 immunex$.mp.
86 granulokin$.mp.
87 nivestim$.mp.
88 tevagrastim$.mp.
89 zarzio$.mp.
90 or/82-89
91 81 or 90
92 51 or 91
93 exp NEOPLASMS BY HISTOLOGIC TYPE/
94 exp NEOPLASMS BY SITE/
95 neoplas$.tw,kf,ot.
96 tumo?r$.tw,kf,ot.
97 (Krebs$ or cancer$).tw,kf,ot.
98 malignan$.tw,kf,ot.
99 (carcino$ or karzino$).tw,kf,ot.
100 karzinom$.tw,kf,ot.
101 sarcom$.tw,kf,ot.
102 leuk#?m$.tw,kf,ot.
103 lymphom$.tw,kf,ot.
104 melano$.tw,kf,ot.
105 metastas$.tw,kf,ot.
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106 (mesothelio$ or mesotelio$).tw,kf,ot.
107 carcinomatos$.tw,kf,ot.
108 (gliom$ or glioblastom$).tw,kf,ot.
109 osteo?sarcom$.tw,kf,ot.
110 (blastom$ or neuroblastom$).tw,kf,ot.
111 or/93-110
112 92 and 111
113 randomized controlled trial.pt.
114 controlled clinical trial.pt.
115 randomi?ed.ab.
116 placebo.ab.
117 clinical trials as topic.sh.
118 randomly.ab.
119 trial.ti.
120 or/113-119
121 humans.sh.
122 120 and 121
123 112 and 122
Appendix 3. EMBASE search strategy
From 1980 to 20 January 2008
1 exp ANTI-BACTERIAL AGENTS/
2 (antibacterial? OR anti-bacterial?).tw.
3 antibio?.tw.
4 (antimicrobial? OR anti-microbial?).tw.
5 (anti-mycobacterial? OR antimyocobacterial?).tw.
6 bacteriocid?.tw.
7 (selective ADJ3 decontaminat?).tw.
8 ANTIBIOTIC PROPHYLAXIS/
9 exp QUINOLONE/
10 fluoroquinilones?.tw.
11 ciprofloxa#in?.tw.
12 ofloxa#in?.tw.
13 norfloxa#in?.tw.
14 enoxa#in?.tw.
15 pefloxa#in?.tw.
16 exp TRIMETHOPRIM/
17 trimethoprim?.tw.
18 sulfamethoxazol?.tw.
19 (trimethoprim-sulfamethoxazol? OR (trimethoprim ADJ3 sulfamethoxazol?)).tw.
20 tmp-smz?.tw.
21 exp POLYMYXIN/
22 colistin?.tw.
23 (nalidixic? ADJ3 acid?).tw.
24 polymyxin?.tw.
25 AMINOGLYCOSIDE/
26 GENTAMICIN/
27 gentami#in?.tw.
28 exp NEBRAMYCIN/
29 tobramy#in?.tw.
30 NEOMYCIN/
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31 neomy#in?.tw.
32 VANCOMYCIN/
33 vancomy#in?.tw.
34 ROXITHROMYCIN/
35 roxithromy#in?.tw.
36 RIFAMPIN/
37 (rifampin? OR rifampicin?).tw.
38 BETA-LACTAMS/
39 PENICILLINS/
40 AMOXICILLIN/
41 CEPHALOTHIN/
42 CEFTRIAXONE/
43 TICARCILLIN/
44 (beta-lactam? OR beta$ lactam$).tw.
45 peni#illin?.tw.
46 amoxi#illin?.tw.
47 (cephalot#in? OR cefalot#in?).tw.
48 ceftriaxone?.tw.
49 ticar#illin?.tw.
50 framycetin?.tw.
51 OR/ 1-50
52 COLONY-STIMULATINGING FACTORS/
53 exp COLONY-STIMULATING FACTORS, RECOMBINANT/
54 exp GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT/
55 exp GRANULOCYTE COLONY-STIMULATING FACTOR/
56 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR/
57 MACROPHAGE COLONY-STIMULATING FACTOR/
58 (rhg#csf? OR rhgm#csf?).tw.
59 (rmethug? OR rhmethug?).tw.
60 (rhug? OR rhugm?).tw.
61 (gcsf? OR g-csf?).tw.
62 (gm-csf? OR gmcsf?).tw.
63 (granulo#yt? ADJ3 fa#tor?).tw.
64 (ma#rophag? ADJ5 fa#tor?).tw.
65 csf.ti
66 filgrastim?.tw.
67 neupogen?.tw.
68 lenograstim?.tw.
69 euprotin?.tw.
70 granocyte?.tw.
71 peg#filgrastim?.tw.
72 neulasta?.tw.
73 leukine?.tw.
74 molgramostine?.tw.
75 mielogen?.tw.
76 leucomax?.tw.
77 OR/ 52-76
78 * LEUKOPENIA/
79 exp AGRANULOCYTOSIS/
80 granulocytopen?.tw.
81 agranulocyto?.tw.
82 neutropen?.tw.
83 leu#open?.tw.
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84 (aplasia OR aplastic OR aplasion).tw.
85 leukocyt? ADJ5 nadir).tw.
86 (neutrophil? ADJ5 nadir).tw.
87 INFECTION/
88 infect?.tw.
89 SEPSIS/
90 (septicemia? OR septicaemia?).tw.
91 (bacteraem? OR bacterem?).tw.
92 FEVER/
93 pyrexia.tw.
94 fever?.tw.
95 FEVER OF UNKNOWNORIGIN/
96 (fever ADJ4 (unknown ADJ3 origin)).tw.
97 PNEUMONIA/
98 ((lung? OR pulmonary?) AND inflammation?).tw.
99 pneumonitis?.tw.
100 engraftment?.tw.
101 (neutrophil? ADJ3 recover?).tw.
102 (hematolog? ADJ3 recover?).tw.
103 (haematology? ADJ3 recover?).tw.
104 OR/ 78-103
105 exp NEOPLASMS BY HISTOLOGIC TYPE/
106 exp NEOPLASMS BY SITE/
107 neoplas?.tw.
108 (tumor? OR tumour?).tw.
109 (krebs? OR cancer?).tw.
110 malignan?.tw.
111 (carcino? OR karzino?).tw.
112 karzinom?.tw.
113 sarcom?.tw.
114 (leukaem? OR leukem?).tw
115 lymphom?.tw.
116 melano?.tw.
117 metastas?.tw.
118 (mesothelio? OR mesotelio?).tw.
119 carcinomatos?.tw.
120 (gliom? OR glioblastom?).tw.
121 osteo?sarcom?.tw.
122 OR/ 105-121
123 CLINICAL TRIAL/
124 RANDOMIZED CONTROLLED TRIALS/
125 RANDOM ALLOCATION/
126 SINGLE-BLIND METHOD/
127 DOUBLE-BLIND METHOD/
128 CROSS-OVER STUDIES/
129 PLACEBOS/
130 Randomi?ed controlled trial$.tw.
131 RCT.tw.
132 random allocation.tw.
133 randomly allocated.tw.
134 Allocated randomly.tw.
135 (allocated ADJ2 random).tw.
136 (allocated ADJ2 random).tw.
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137 single blind$.tw.
138 double blind$.tw.
139 ((treble or triple) ADJ blind$).tw.
140 placebo$.tw.
141 PROSPECTIVE STUDIES/
142 OR/ 123-141
143 CASE STUDY/
144 case report.tw.
145 ABSTRACT REPORT/ OR LETTER/
146 OR/ 143-145
147 142 NOT 146
148 ANIMAL/
149 HUMAN/
150 148 NOT 149
151 147 NOT 150
152 51 OR 77
153 104 AND 122
154 152 AND 153
155 154 AND 51
WH A T ’ S N E W
Last assessed as up-to-date: 3 December 2015.
Date Event Description
28 August 2015 New citation required but conclusions have not changed New search
28 August 2015 New search has been performed New search, inclusion criteria adapted, RoB adapted
C O N T R I B U T I O N S O F A U T H O R S
Nicole Skoetz: data extraction and analysis, drafting of final review
Julia Bohlius: content input
Ina Monsef: database search
Oliver Blank: data extraction and analysis
Andreas Engert: clinical expertise and content input
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Outcomes:
We did not evaluate secondary prophylaxis as we identified only two trials, assessing G-CSF or GM-CSF and antibiotics for primary
prophylaxis.
Data analysis:
We did not identify time-to-event outcomes and continuous data. For time-to-event outcomes, we would have extracted hazard ratios
(HRs) from published data according to Parmar and Tierney (Parmar 1998; Tierney 2007). We would have calculated continuous
outcomes as standardised mean differences.
As we included only one trial in each comparison, we could not pool the data. If we identify more trials for future updates, we will
check whether the data are sufficiently similar to be combined. Then, we will pool results by applying meta-analyses using the fixed-
effect model, and the random-effects model as a sensitivity analysis.
If the trials are too clinically heterogeneous to combine, we will only perform subgroup analyses, without calculating an overall estimate.
We will analyse data according to Cochrane recommendations (Deeks 2011), and will use the Cochrane statistical package in Review
Manager 5 for analysis (Review Manager (RevMan)).
Assessment of heterogeneity:
As we did not meta-analyse the data, we did not assess heterogeneity. If we perform a meta-analysis in a future update, we will identify
heterogeneity by using a Chi² test with a significance level at P < 0.1. We will use the I² statistic to quantify possible heterogeneity
(I² > 30% moderate heterogeneity, I² > 75% considerable heterogeneity; Deeks 2011). Moreover, we will explore potential causes of
heterogeneity by sensitivity and subgroup analyses.
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N O T E S
Somepassages in this review, especially in themethods part, are from the standard template of theCochraneHaematologicalMalignancies
Review Group.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols [adverse effects]; Fever [prevention & control]; Granulo-
cyte Colony-Stimulating Factor [∗therapeutic use]; Granulocyte-Macrophage Colony-Stimulating Factor [∗therapeutic use]; Infection
Control [∗methods]; Neoplasms [∗drug therapy; mortality]; Neutropenia [prevention & control]; Randomized Controlled Trials as
Topic
MeSH check words
Humans
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